Sector News

Allergan promises independent board chair in next leadership change

March 25, 2019
Life sciences

Allergan Plc on Friday agreed to split its chairman and chief executive roles, but only at its next leadership change, as the drugmaker pushed back against claims from activist hedge fund Appaloosa LP that an independent chair could help current CEO Brent Saunders boost the company’s sagging share price.

Saunders, 49, put together the current version of Allergan through a series of deals to roll up several pharmaceutical companies in 2014, and has run the company since then.

He has no plans to step down, a source close to Allergan said.

The company said on Friday that splitting the roles now – as Appaloosa has requested – “could impede the board’s effectiveness by creating a crisis of confidence in Mr. Saunders at a time when leadership stability and effectiveness is critical.”

The Botox maker announced the change in its annual proxy statement, filed with the Securities and Exchange Commission late on Friday afternoon.

Appaloosa, led by billionaire hedge fund manager David Tepper, has been agitating for changes at Allergan since last year as Allergan’s shares have sagged. Beyond the proposal to separate the chairman and CEO roles, Appaloosa has said the drugmaker should consider a sale or breakup.

A spokesman for Tepper did not immediately respond to a request for comment.

Allergan’s shares are off around 24 percent since October and are trading at less than half their historic high of over $330 hit in 2015. On Friday, they fell 2.8 percent to $149.30.

The company has recently disappointed investors due to a worse than expected revenue forecast for 2019 and the failure of depression treatment rapastinel earlier this month.

The company undertook a review of its corporate strategy last year, but the result of that review may only be the sale of its relatively small infectious diseases unit and a commitment to remain disciplined in its spending.

Allergan said in the regulatory filing that it had formed a board committee to oversee mergers, acquisitions, divestitures and other transactions. Robert Hugin, the former CEO of drugmaker Celgene Corp, will helm that committee.

The company also said director Catherine Klema will not be standing for re-election. If the company replaces Klema, it will have named five new directors to its 12-person board since the beginning of last year.

By Michael Erman and Saumya Sibi Joseph

Source: Reuters

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend